Benitec Biopharma Inc. — Form 10-Q Summary
Reporting period: Quarter and nine months ended March 31, 2022 (fiscal 2022 third quarter; not 2021 Q3 as stated in the request metadata). Unless noted, financial amounts are in U.S. dollars.
Business context
Benitec is a development-stage biotechnology company developing genetic medicines using its DNA-directed RNA interference (ddRNAi) platform. Its lead candidate, BB-301, is an AAV-based “silence and replace” therapy for oculopharyngeal muscular dystrophy (OPMD). The company has no approved products and has not generated product-sales revenue.
Financial results and liquidity
| Metric | Three months ended March 31, 2022 | Nine months ended March 31, 2022 | Comparable 2021 period |
|---|---|---|---|
| Revenue | $48,000 | $73,000 | $1,000 quarterly; $57,000 nine months |
| Research and development | $2.171 million | $8.096 million | $2.758 million quarterly; $4.700 million nine months |
| General and administrative | $1.337 million | $5.093 million | $1.029 million quarterly; $4.976 million nine months |
| Operating loss | $3.460 million | $13.116 million | $3.793 million quarterly; $9.741 million nine months |
| Net loss | $3.275 million | $13.141 million | $3.909 million quarterly; $9.879 million nine months |
| Basic and diluted loss per share | $0.40 | $1.61 | $0.82 quarterly; $2.93 nine months |
For the nine months, operating cash use was $11.044 million, versus $7.675 million in 2021. Investing cash flow was zero, and there was no financing cash flow, compared with $9.854 million of net financing cash in the prior-year period. Cash fell from $19.769 million at June 30, 2021 to $8.630 million at March 31, 2022. The filing reports no borrowings or credit facility. Lease liabilities totaled $867,000, including $232,000 current and $635,000 non-current.
Current assets were $8.841 million and current liabilities $1.909 million at March 31, 2022. Despite this positive current-asset balance, management states cash is insufficient to fund operations for the next 12 months without additional financing and identifies substantial doubt about the company’s ability to continue as a going concern. Accumulated deficit was $143.260 million. Profit margins are not meaningful given the company’s minimal licensing revenue and continuing losses.
Material changes versus the prior comparable period
- Nine-month R&D expense increased 72% to $8.096 million, reflecting BB-301 nonclinical Beagle studies and commercial-scale GMP manufacturing; quarterly R&D expense declined year over year as study milestones were reached and related costs fell.
- Nine-month net loss increased to $13.141 million from $9.879 million, while quarterly net loss narrowed to $3.275 million from $3.909 million.
- G&A expense was modestly higher for the nine months, with management citing insurance, consultant, legal and accounting costs, and share-based compensation.
- Cash declined by $11.139 million over the nine-month period. There was no current-period equity financing, unlike the prior-year period.
- In August 2021, the company extended its office lease through June 2025, increasing recorded right-of-use assets and lease liabilities.
Outlook, management commentary and risks
- Management stated that BB-301’s clinical development program was expected to begin in 2022. The proposed first-in-human Phase 1b/2a study is an open-label dose-escalation study, preceded by a six-month OPMD natural-history observation period and followed by 52 weeks of post-dose monitoring.
- The BB-301 Pilot Dosing Study in Beagle dogs was reported completed without incident. Interim molecular analyses covered 16 of 24 subjects; management reported substantially improved pharyngeal-muscle transduction versus the former licensee’s study. The final data set was to be presented in a peer-reviewed format. These are company-reported preclinical findings, not clinical efficacy results.
- The company reported completing pre-CTA/pre-IND regulatory interactions with Health Canada, France’s ANSM and the FDA. BB-301 has Orphan Drug Designation in the United States and European Union.
- Management intends to fund operations with existing cash and additional capital, but states financing is not assured. If funding is unavailable or results fall short, the company may reduce or delay spending, delay development milestones or cease operations.
- Key risks include clinical and regulatory uncertainty, reliance on third parties and collaborators, competition, intellectual-property protection, supply-chain disruption and possible COVID-19-related delays. The filing says there were no material changes to the risk factors in the prior Form 10-K.
- No material legal proceedings or subsequent events requiring disclosure were reported. Disclosure controls were assessed as effective, with no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Whether and when the company secured financing sufficient to address the disclosed 12-month liquidity shortfall and going-concern uncertainty.
- Actual timing and status of the OPMD natural-history study, clinical-trial filings and Phase 1b/2a BB-301 study relative to the stated 2022 plans.
- Final, peer-reviewed Pilot Dosing Study results and the scope and outcomes of the remaining BB-301 nonclinical and manufacturing work.
- Future cash burn, R&D commitments and the effect of additional financing on existing shareholders.
- Whether licensing revenue or other collaborations become material; reported revenue to date was minimal and was not from product sales.